Navigation Links
BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy
Date:10/30/2013

A review article by researchers at Boston University School of Medicine (BUSM) suggests that epigenetics may be a useful target to stop the growth, spread and relapse of cancer. The findings are published online in Volume 14 of the International Journal of Molecular Science.

The term epigenetics refers to the external modifications to DNA that turn genes "on" or "off." These modifications do not change the DNA sequence, but instead, they affect how cells read genes.

The researchers propose that epigenetic and other changes mediate the development of cancer progenitor cells. These cells represent the early stage of cancer cell development and can grow rapidly to become full-fledged cancer. According to the researchers, progression of different cancer stages and development of metastatic potential requires differentiation of these cancer progenitor cells.

"These findings are not only important in understanding how cancer progresses, but also help in understanding how cancer progenitor cells grow and differentiate via epigenetic regulators," said Sibaji Sarkar, PhD, instructor of medicine at BUSM.

Mutated cells are more vulnerable to the environment. Some of these mutations may alter epigenetic regulation in addition to epigenetic changes occurring by external and internal influences, which impacts gene expression and regulates cell behavior, playing a profound role when normal cells develop into progenitor cancer cells.

Sarkar and his colleagues hypothesize that when the progenitor cancer cells metastasize, rapid growth halts. When differentiation is complete, the rapid growth resumes.

The researchers believe that epigenetic mechanisms are involved in this process. Once a degree of metastatic form of cancer is achieved, the genes, which cause the change, become inactive and the genes causing rapid growth are again turned on.

"The acknowledgement of epigenetic changes as key regulators of this switching is expected to generate better epigenetic drugs. It has been suggested that epigenetic drug treatment in combination with standard chemotherapeutic drugs may have better outcomes in preventing and treating drug-resistant cancers," he added.


'/>"/>

Contact: Gina Orlando
gina.orlando@bmc.org
617-638-8490
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Researchers quantify toxic ocean conditions during major extinction 93.9 million years ago
2. Researchers discover how cancer invisibility cloak works
3. Oregon researchers say supplement cuts muscle loss in knee replacements
4. BUSM researchers identify molecule that could aid lung cancer detection, treatment
5. Researchers identify gene variant that raises risk for colorectal cancer from eating processed meat
6. Researchers show how plants tell the time
7. Berkeley Lab researchers get a detailed look at a DNA repair protein in action
8. Researchers capture images of open channel that moves proteins across cell membranes
9. UAlberta medical researchers discover potential new treatment for colitis
10. Older siblings cells can be passed from female dogs to their puppies in the womb, MU researchers find
11. Nitrogen fertilizer remains in soils and leaks towards groundwater for decades, researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology , ... recognition technologies, today announced that the MegaMatcher On ... was submitted for the NIST Minutiae Interoperability ... all the mandatory steps of the evaluation protocol. ... a continuing test of fingerprint templates used to ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... China Cord Blood Corporation (NYSE: CO ... leading provider of cord blood collection, laboratory testing, hematopoietic stem ... results of its 2016 Annual General Meeting, which was held ... China . At the Annual General ... KPMG Huazhen LLP as the independent auditors of the Company ...
(Date:12/8/2016)... Board of Directors of the Pittsburgh Life Sciences ... only pure life sciences investment firm, today announced a ... developed by the Nominating and Governance Committee over the ... Jordan is selected to serve as President and ... who is elected to the position of Executive Chairman ...
(Date:12/8/2016)... DIEGO, Dec. 8, 2016  OncoSec Medical Incorporated ... developing DNA-based intratumoral cancer immunotherapies, today announced financial ... "We are delivering on our commitment ... with ImmunoPulse┬« IL-12. We are pleased with the ... combination trial, and we are focused on advancing ...
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
Breaking Biology Technology: